Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

A (Slight) Liberalization of Communications with Docs from FDA

What Happened. This week FDA issued a new final Guidance related to communications about medical products that, while representing a slight liberalization of regulation when it comes to discussing useful information about a drug and the cleared uses for it, but which may not be included in the label. That said, the guidance does not address the issue of off-label promotions – or discussions that involve aspects of the product for uses in which it has not been cleared. The utility of the new guidance is that it will allow firms to talk about things – such as post-marketing study outcomes – that will enhance the understanding of the on-label use of the product. 

What it Says.

The balance of the guidance provide specific examples to more sharply define the parameters of how the agency applies the assessment of a communication by the company that is about information not included in the label, but which is not involving an off-label use. 

Implications and Insights for Pharma. In considering how the new guidance may impact the communications by pharma companies, it is important to take into account where violations have occurred in the past. It is notable that FDA has issued this guidance during a time when enforcement by the agency is at a standstill with only a single enforcement letter having been issued by the Office of Prescription Drug Promotion (OPDP) so far during 2018 and following a record low of 6 last year. In reviewing FDA enforcement since 2004, out of the 324 letters issued by OPDP (or under its predecessor name DDMAC – the Division of Drug, Marketing, Advertising and Communications) by my count only 18 letters involved a violation of promotion of an unapproved use. Of those, 7 involved oral statements, mostly by sales representatives, though one involved a company CEO in a media interview.  Other violations almost exclusively involved communications vehicles aimed primarily at physicians, such as Dear Doctor letters, direct mail or sales aids. So while the new guidance pertains to all communications by companies to physicians, because the most common violation occurred in the contest of an oral statement, particular care might be taken by companies to train spokespeople with regard to the parameters of the new guidance. 

Photo by rawpixel on Unsplash

Share this:
Share this page via EmailShare this page via Stumble UponShare this page via Digg thisShare this page via FacebookShare this page via Twitter

This post first appeared on Eye On FDA, please read the originial post: here

Share the post

A (Slight) Liberalization of Communications with Docs from FDA


Subscribe to Eye On Fda

Get updates delivered right to your inbox!

Thank you for your subscription